Category Archives: Market Access

Drug Pipelines in Canada: Is There a Buyer for Future Innovation?

By Clark Herman | Published: April 15, 2013
Last week, Canada’s National Prescription Drug Utilization Information System (NPDUIS), a federal-provincial fact-finding panel that works closely with the Patented Medicines Prices Review Board (PMPRB), issued its fourth New Drug Pipeline Monitor (NDPM) looking at drugs currently under development that may have an impact on future drug expenditures. The report is another example of how [...]
Also posted in Global, IP, Orphan Drugs, R&D, Regulatory, healthcare, pricing | Tagged , , , , , | Leave a comment

The Patent Black Label: Six Side-Effects of India's Novartis Glivec Ruling

By William Looney | Published: April 3, 2013
Monday’s decision by India’s Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve – but the implications in and beyond India are both immediate and lasting.  Here’s a list of six that Pharm Exec thinks are most important:
Also posted in Emerging Markets, Global, IP, Legal, Manufacturing, Strategy, pricing | Tagged , , , , , , , , | 6 Comments

The FTC's Beef with Pay For Delay: What's the Fuss?

By Clark Herman | Published: March 26, 2013
Yesterday, the Supreme Court heard arguments on the matter of pay-for-delay settlements between patent holders and generic firms. The Federal Trade Commission (FTC) hopes to overturn the 11th federal circuit’s ruling that such settlements are not anti-competitive on the grounds that these settlements amount to a restraint of trade under the commerce clause of the [...]
Also posted in IP, Legal, Regulatory | Tagged , , , , | 1 Comment

FTC v. Actavis: The Wrong End of the Telescope

By Guest Blogger | Published: March 25, 2013
by Traci Medford-Rosow and Peter C. Richardson On December 8, 2012, the Supreme Court agreed to hear the Federal Trade Commission (FTC) v. Actavis, Inc. case. The court’s grant of certiorari marked the latest chapter in a decade-long effort by the FTC to have the court rule on the festering issue of whether pay-for-delay provisions in [...]
Also posted in IP, Legal, Op-Ed, Regulatory, Strategy | Tagged , | 1 Comment

Are US and Canadian Rx Policies Converging?

By Guest Blogger | Published: March 19, 2013
by Tom Norton As the US pharmaceutical industry anxiously watches the rapid onset of Obamacare, certainly one of the more pressing issues is the debate over the number of drugs that will be reimbursed in each therapeutic class under the Essential Health Benefits (EHB) program.  To say that this is a critical concern for the future [...]
Also posted in Global, Guest Blog, Legal, Strategy, healthcare | Tagged , , , , , , | Leave a comment